Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126527492 | 12652749 | 2 | F | 20160729 | 20160825 | 20160815 | 20160907 | EXP | DE-ELI_LILLY_AND_COMPANY-DE201608000266 | ELI LILLY AND CO | 67.00 | YR | M | Y | 67.50000 | KG | 20160906 | MD | DE | DE |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126527492 | 12652749 | 1 | PS | CYRAMZA | RAMUCIRUMAB | 1 | Intravenous (not otherwise specified) | 8 MG/M2, CYCLICAL | N | 0 | 8 | MG/M**2 | INTRAVENOUS INFUSION | ||||||
| 126527492 | 12652749 | 2 | SS | PACLITAXEL. | PACLITAXEL | 1 | UNK | 0 | |||||||||||
| 126527492 | 12652749 | 3 | C | ACTRAPID | INSULIN HUMAN | 1 | UNK | 0 | |||||||||||
| 126527492 | 12652749 | 4 | C | ASPIRIN. | ASPIRIN | 1 | UNK | 0 | |||||||||||
| 126527492 | 12652749 | 5 | C | PRAVASIN | PRAVASTATIN SODIUM | 1 | UNK | 0 | |||||||||||
| 126527492 | 12652749 | 6 | C | METAMIZOL /06276702/ | METAMIZOLE | 1 | UNK | 0 | |||||||||||
| 126527492 | 12652749 | 7 | C | INNOHEP | TINZAPARIN SODIUM | 1 | UNK | 0 | |||||||||||
| 126527492 | 12652749 | 8 | C | MCP | METOCLOPRAMIDE HYDROCHLORIDE | 1 | UNK | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126527492 | 12652749 | 1 | Oesophageal adenocarcinoma |
| 126527492 | 12652749 | 2 | Oesophageal adenocarcinoma |
| 126527492 | 12652749 | 3 | Type 2 diabetes mellitus |
| 126527492 | 12652749 | 4 | Coronary artery disease |
| 126527492 | 12652749 | 5 | Lipid metabolism disorder |
| 126527492 | 12652749 | 6 | Pain |
| 126527492 | 12652749 | 7 | Anticoagulant therapy |
| 126527492 | 12652749 | 8 | Antiemetic supportive care |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126527492 | 12652749 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126527492 | 12652749 | Blood glucose increased | |
| 126527492 | 12652749 | Febrile neutropenia | |
| 126527492 | 12652749 | Haemoglobin decreased | |
| 126527492 | 12652749 | Pneumonia | |
| 126527492 | 12652749 | White blood cell count decreased |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 126527492 | 12652749 | 1 | 20160718 | 20160725 | 0 | |
| 126527492 | 12652749 | 2 | 20160718 | 0 | ||
| 126527492 | 12652749 | 6 | 20160725 | 0 | ||
| 126527492 | 12652749 | 7 | 20160713 | 0 | ||
| 126527492 | 12652749 | 8 | 20160722 | 0 |